Target intelligence / Profile preview

Mitochondrial dicarboxylate carrier (SLC25A10)

Target
SLC25A10
Molecular classification
Transporter, Solute carrier, Mitochondrial carrier protein
01

Overview

The **mitochondrial dicarboxylate carrier (SLC25A10)** is an integral membrane transporter protein of the inner mitochondrial membrane encoded by the SLC25A10 gene[1][2][3]. It exchanges dicarboxylates such as malate, succinate, and malonate for phosphate, sulfate, and thiosulfate using an antiport mechanism, playing a central role in metabolite shuttling for the Krebs cycle, gluconeogenesis, urea synthesis, fatty acid metabolism, and sulfur metabolism[1][2][3]. SLC25A10 modulates lipid homeostasis in adipocytes and liver, influences insulin sensitivity, maintains cellular redox and energy homeostasis, and interacts with pathways critical in cancer and metabolic diseases[1][3]. Loss-of-function mutations can result in severe mitochondrial disease and neurodegenerative disorders, and the transporter is considered a therapeutic target in metabolic syndrome, cancer, and diabetes[1][2][3].

Other names
mitochondrial dicarboxylate carrierDICdicarboxylate ion carriersolute carrier family 25 member 10SLC25A10MTDPS19SLC25A10 proteindicarboxylate transporter
02

Mechanism of action

Competitive inhibition of dicarboxylate transport (by analogues); Inhibition increases sensitivity to oxidative stress and traditional anticancer drugs in tumors

03

Biological functions

Dicarboxylate transport across mitochondrial inner membraneRegulation of fatty acid metabolismGluconeogenesisUrea synthesisSulfur metabolismRegulation of redox homeostasisRegulation of insulin sensitivity
04

Disease associations

CancerMitochondrial diseaseNeurodegenerative diseaseObesity/metabolic syndromeDiabetic nephropathy
05

Safety considerations

Disruption of SLC25A10 results in impaired Krebs cycle, lipid metabolism, and increased oxidative injuryDeficiency can cause severe mitochondrial dysfunction and neurodegenerative disease
06

Interacting drugs

Dicarboxylate analogues (e.g., butylmalonate)

4 more in the full profile.

07

Biomarkers

Upregulation in tumors (potential biomarker for metabolic reprogramming/cancer)Expression levels as a marker for metabolism-related pathologies

Beyond the preview

Go deeper on Mitochondrial dicarboxylate carrier (SLC25A10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial dicarboxylate carrier (SLC25A10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call